

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 March 2004 (04.03.2004)


PCT

(10) International Publication Number  
WO 2004/018441 A1

- (51) International Patent Classification<sup>7</sup>: C07D 265/30, 413/10, A61K 31/5375, A61P 25/00
- (21) International Application Number: PCT/US2003/023270
- (22) International Filing Date: 18 August 2003 (18.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0219687.1 23 August 2002 (23.08.2002) GB  
60/415,305 1 October 2002 (01.10.2002) US
- (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CASES-THOMAS, Manuel, Javier [ES/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB). HAUGHTON, Helen, Louise [GB/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB). LAMAS-PETEIRA, Carlos [ES/ES]; Lilly S. A., Avenida de la Industria, 30, E-28100 Alcobendas (ES). OUWERKERK-MAHADEVAN, Sivi [NL/BE]; Lilly MSG Development Centre, S. A., Parc Scientifique de Louvain-la-Neuve, 11, Rue Granbompre, B-1348 Mont-Sai (BE). MASTERS, John, Joseph [US/US]; 12047 Flint Stone Court, Fishers, IN 46038 (US). SIMMONDS, Robin, George [GB/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB). RUDYK, Hélène, Catherine, Eugénie [FR/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB). WALTER, Magnus, Wilhelm [DE/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB).
- (74) Agents: WELCH, Lawrence, T. et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

[Continued on next page]

(54) Title: ARYL AND HETEROARYL MORPHOLINE DERIVATIVES



(57) Abstract: Compounds of formula (I) are selective inhibitors of the reuptake of norepinephrine, wherein Rx is H; Ry is H or C<sub>1</sub>-C<sub>4</sub> alkyl; each Rz is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl; X represents O; Y represents OH or OR; R is C<sub>1</sub>-C<sub>4</sub> alkyl; and Ar<sub>1</sub> and Ar<sub>2</sub> are optionally substituted phenyl or 5- or 6-membered heteroaryl rings.